EyeGate Receives Additional Milestone Payment From Valeant Pharmaceuticals


Eyegate Pharmaceuticals, Inc. recently announced that it has received an additional development milestone from Valeant Pharmaceuticals Luxembourg under the company’s license agreement with Valeant for the development and commercialization of the company’s EGP-437 combination product in the field of uveitis.

The company is eligible to receive milestone payments totaling up to $32.5 million upon and subject to the achievement of certain specified developmental and commercial milestones.

“I am pleased with the progress we have made in our collaboration with Valeant. This milestone payment is a reflection of the continued advancement of EyeGate’s drug development initiatives and further demonstrates the utility of our lead candidate, EGP-437 combination product, in anterior uveitis,” Stephen From, President and Chief Executive Officer of EyeGate Pharmaceuticals.

EyeGate is a clinical-stage specialty pharmaceutical company that is focused on developing and commercializing therapeutics and drug delivery systems for treating diseases of the eye. EGP-437, the company’s first and only product in clinical trials, incorporates a reformulated topically active corticosteroid, Dexamethasone Phosphate, that is delivered into the ocular tissues through EyeGate’s proprietary innovative drug delivery system, the EyeGate(R) II Delivery System. For more information, visit www.EyeGatePharma.com